Conversely, the eight genes preferentially mutated in DLBCL with good outcomes align with their roles as markers for genetic subtypes associated with favorable prognosis, including BN2, ST2, and EZB [23, 24]. The gene discussed is BNC2; the disease is diffuse large B-cell lymphoma.